Impact of baseline liver function on survival outcomes in patients with unresectable hepatocellular carcinoma (uHCC) treated with camrelizumab + rivoceranib vs sorafenib: A post hoc analysis of study CARES-310.

医学 析因分析 索拉非尼 内科学 肝细胞癌 胃肠病学 肝功能 事后 外科
作者
Arndt Vogel,Ann‐Lii Cheng,Wei Shi,Seong Ho Jang,Laura E. Crotty Alexander,Xianzhang Meng,N Raphael,Stephen L. Chan
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:42 (3_suppl): 509-509
标识
DOI:10.1200/jco.2024.42.3_suppl.509
摘要

509 Background: CARES-310 study (NCT03764293) evaluated the combination of camrelizumab, an anti-PD-1 inhibitor, and rivoceranib, a highly selective VEGFR-2 tyrosine kinase inhibitor, (cam + rivo) vs sorafenib (sora) for the treatment of uHCC. Cam + rivo significantly improved median overall survival ([mOS] 22.1 months [mo] vs 15.1 mo) and median progression-free survival ([mPFS] 5.6 mo vs 3.7 mo) compared to sora. This post-hoc analysis evaluated the impact of baseline albumin-bilirubin (ALBI) grade and Child-Pugh (CP) class on survival outcomes. Methods: In this randomized, open-label, international, multicenter, phase 3 study, patients were randomized 1:1 to receive cam 200 mg IV Q2W + rivo 250 mg PO QD (n=272) or sora 400 mg PO BID (n=271). Median overall survival (mOS), median progression free survival (mPFS), objective response rate (ORR), disease control rate (DCR), and safety were assessed by baseline ALBI grade and CP class. Results: mOS, mPFS, DCR, and ORR improved with cam + rivo vs sora regardless of baseline liver function (Table). Although treatment-related grade 3/4 AEs occurred at a greater rate in the cam + rivo arm vs the sora arm, the rate of these events was similar for patients with baseline ALBI grade 1 and grade 2 (cam + rivo, 82.1% and 81.7% vs sora, 53.9% and 54.0%, respectively). Median time-to-deterioration (mTTD) to CP class B was similar between treatment arms for ALBI grade 1 (not evaluable [NE], NE) and grade 2 (cam + rivo, 10.1 mo; sora, 10.6 mo; HR, 0.99). Conclusions: In this post-hoc analysis of Study CARES-310, the efficacy of cam + rivo was superior to sora regardless of baseline liver function as measured by both ALBI grade and CP class. Despite a higher rate of grade 3/4 AEs, there was no detrimental effect of cam +rivo on liver function in patients with both well- and moderately- preserved liver function compared to sora. These results support cam + rivo as a potential new first-line treatment option for patients with uHCC regardless of baseline liver function. Clinical trial information: NCT03764293 . [Table: see text]
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
2秒前
LHT完成签到,获得积分10
3秒前
落寞凌波发布了新的文献求助10
7秒前
桐桐应助幸福的杨小夕采纳,获得10
12秒前
韩麒嘉完成签到 ,获得积分10
14秒前
聪慧的凝海完成签到 ,获得积分0
23秒前
23秒前
wwb发布了新的文献求助10
26秒前
phil完成签到 ,获得积分10
26秒前
34秒前
高高菠萝完成签到 ,获得积分10
34秒前
滴滴滴完成签到 ,获得积分10
34秒前
yangsi完成签到 ,获得积分10
37秒前
量子星尘发布了新的文献求助10
38秒前
41秒前
酷炫葵阴发布了新的文献求助10
46秒前
ORANGE完成签到,获得积分10
48秒前
思源应助松松采纳,获得20
52秒前
共享精神应助酷炫葵阴采纳,获得10
54秒前
丝丢皮得完成签到 ,获得积分10
55秒前
56秒前
xfy完成签到,获得积分10
1分钟前
阳炎完成签到,获得积分10
1分钟前
行云流水完成签到,获得积分10
1分钟前
1分钟前
冷酷尔琴发布了新的文献求助10
1分钟前
青水完成签到 ,获得积分10
1分钟前
量子星尘发布了新的文献求助10
1分钟前
1分钟前
冷酷尔琴完成签到,获得积分10
1分钟前
onevip完成签到,获得积分0
1分钟前
小莫完成签到 ,获得积分10
1分钟前
1分钟前
theseus完成签到,获得积分10
1分钟前
胡楠完成签到,获得积分10
1分钟前
北国雪未消完成签到 ,获得积分10
1分钟前
李振博完成签到 ,获得积分10
1分钟前
1分钟前
雪妮完成签到 ,获得积分10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038029
求助须知:如何正确求助?哪些是违规求助? 3575740
关于积分的说明 11373751
捐赠科研通 3305559
什么是DOI,文献DOI怎么找? 1819224
邀请新用户注册赠送积分活动 892652
科研通“疑难数据库(出版商)”最低求助积分说明 815022